Sanofi S.A. (SNY – Q4FY19 & FY19) – Strong growth from Dupixent and Vaccines sales.

in , on May 22, 2020

Sanofi and Regeneron Pharmaceuticals, Inc.announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab) to platinum doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) that tested positive for PD-L1 in ≥50% of tumor cells. Based on a recommendation by the independent Data Monitoring Committee to stop the trial early, the trial will be modified to allow all patients to receive Libtayo for this investigational use.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q4FY19 Results – Overview
– FY19 Results – Overview
– Q4FY19 & FY19 – Geographic Revenue
– Q4FY19- Segment Performance
– FY19 – Segment Performance
– Q4FY19 – R&D Update
– Guidance
– Conclusion

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

Release Information

  • Released

    May 22, 2020

  • Last Updated

    May 22, 2020